EPISODE · Jun 10, 2021 · 50 MIN
Analyzing the atai Life Sciences IPO
from Business Trip · host Greg Kubin & Matias Serebrinsky
Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss:How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risksLinks to topics in this episode:Atai life sciencesEtifoxineEsketamine & arketamineAtai’s S-1Psychedelic Pharmacist AssociationCalyx LawPsilocybin Alpha, Noetic Fundkratom, Salvinorin A, BNC210, mitragynineMike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter ThielPureTech Health, Akili Interactive LabsBT’s DemeRx EpisodeViridia Life Sciences, EmpathBio, Kures, Recognify Life SciencesRead the transcript here.Watch episode 9 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by
Embed this episode
What this episode covers
Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss: How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risks Links to topics in this episode: Atai life sciences Etifoxine Esketamine & arketamine Atai’s S-1 Psychedelic Pharmacist Association Calyx Law Psilocybin Alpha, Noeti...
Ready to play
Analyzing the atai Life Sciences IPO
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.